KanekaQ10? To Be Used In Phase III Clinical Trial On Coenzyme Q10’s Effects On Huntington’s Disease
Jun 10th 2008Drug InformationHuntingtons Disease
The Huntington Study Group has launched a Phase III clinical trial, funded by the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health [NIH]), to determine the effect of the maximum effective dosage of Coenzyme Q10 on cognitive function in individuals with Huntington’s Disease (HD). They will also examine the long-term safety of CoQ10.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
